Intracellular activation of 4-hydroxycyclophosphamide into a DNA-alkylating agent in human leucocytes

References

• Ataya KM, Pydyn EF, Ramahi-Ataya AJ. 1990. The effect of “activated” cyclophosphamide on human and rat ovarian granulosa cells in vitro. Reprod Toxicol. 4(2):121–125.
   PubMed Web of Science ®Google Scholar
• Azevedo MF, Faucz FR, Bimpaki E, Horvath A, Levy I, de Alexandre RB, Ahmad F, Manganiello V, Stratakis CA. 2014. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev. 35(2):195–233.
   PubMed Web of Science ®Google Scholar
• Berd D, Mastrangelo MJ. 1988. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res. 48(6):1671–1675.
   PubMed Web of Science ®Google Scholar
• Bielicki L, Voelcker G, Hohorst HJ. 1983. Enzymatic toxicogenation of “activated” cyclophosphamide by 3'-5' exonucleases. J Cancer Res Clin Oncol. 105(1):27–29.
   PubMed Web of Science ®Google Scholar
• Bielicki L, Voelcker G, Hohorst HJ. 1984. Activated cyclophosphamide: an enzyme-mechanism-based suicide inactivator of DNA polymerase/3'-5' exonuclease. J Cancer Res Clin Oncol. 107(3):195–198.
   PubMed Web of Science ®Google Scholar
• Bischoff E. 2004. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res. 16 (Suppl 1):S11–S14.
   PubMed Web of Science ®Google Scholar
• Borch RF, Millard JA. 1987. The mechanism of activation of 4-hydroxycyclophosphamide. J Med Chem. 30(2):427–431.
   PubMed Web of Science ®Google Scholar
• Brieba LG. 2008. Template dependent human DNA polymerases. Curr Top Med Chem. 8(15):1312–1326.
   PubMed Web of Science ®Google Scholar
• Büyüknacar HS, Kumcu EK, Göçmen C, Onder S. 2008. Effect of phosphodiesterase type 4 inhibitor rolipram on cyclophosphamide-induced cystitis in rats. Eur J Pharmacol. 586(1-3):293–299.
   PubMed Web of Science ®Google Scholar
• Colvin M, Brundrett RB, Kan M-NN, Jardine I, Fenselau C. 1976. Alkylating properties of phosphoramide mustard. Cancer Res. 36(3):1121–1126.
   PubMed Web of Science ®Google Scholar
• Crook TR, Souhami RL, McLean AEM. 1986. Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells. Cancer Res. 46(10):5029–5034.
   PubMed Web of Science ®Google Scholar
• Cushnir JR, Naylor S, Lamb JH, Farmer PB, Brown NA, Mirkes PE. 1990. Identification of phosphoramide mustard/DNA adducts using tandem mass spectrometry. Rapid Commun Mass Spectrom. 4(10):410–414.
   PubMed Web of Science ®Google Scholar
• Emadi A, Jones RJ, Brodsky RA. 2009. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 6(11):638–647.
   PubMed Web of Science ®Google Scholar
• Engels C, Schwab C, Zhang J, Stevens MJA, Bieri C, Ebert M-O, McNeill K, Sturla SJ, Lacroix C. 2016. Acrolein contributes strongly to antimicrobial and heterocyclic amine transformation activities of reuterin. Sci Rep. 6(1):36246.
   PubMed Web of Science ®Google Scholar
• Fleer R, Brendel M. 1982. Toxicity, interstrand cross-links and DNA fragmentation induced by “'activated' cyclophosphamide in yeast: comparative studies on 4-hydroperoxy-cyclophosphamide, its monofunctional analogon, acrolein, phosphoramide mustard, and nor-nitrogen mustard”. Chem Biol Interact. 39(1):1–15.
   PubMed Web of Science ®Google Scholar
• Frey MW, Nossal NG, Capson TL, Benkovic SJ. 1993. Construction and characterization of a bacteriophage T4 DNA polymerase deficient in 3'->5' exonuclease activity. Proc Natl Acad Sci USA. 90(7):2579–2583.
   PubMed Web of Science ®Google Scholar
• Glavas NA, Ostenson C, Schaefer JB, Vasta V, Beavo JA. 2001. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc Natl Acad Sci USA. 98(11):6319–6324.
   PubMed Web of Science ®Google Scholar
• Groehler A, 4th Villalta PW, Campbell C, Tretyakova N. 2016. Covalent DNA-protein cross-linking by phosphoramide mustard and nornitrogen mustard in human cells. Chem Res Toxicol. 29(2):190–202.
   PubMed Web of Science ®Google Scholar
• Helsby NA, Yong M, van Kan M, de Zoysa JR, Burns KE. 2019. The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes. Br J Clin Pharmacol. 85(9):1925–1934.
   PubMed Web of Science ®Google Scholar
• Heylmann D, Bauer M, Becker H, van GS, Bacher N, Steinbrink K, Kaina B. 2013. Human CD4 + CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response. PLOS One. 8(12):e83384.
   PubMed Web of Science ®Google Scholar
• Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, Li D, Cherian S, Chen X, Pender BS, Hawkins RM, et al. 2019. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 133(17):1876–1887.
   PubMed Web of Science ®Google Scholar
• Jardine I, Fenselau C, Appler M, Kan M-N, Brundrett RB, Colvin M. 1978. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. Cancer Res. 38(2):408–415.
   PubMed Web of Science ®Google Scholar
• Kato K, Takeuchi A, Akashi K, Eto M. 2019. Cyclophosphamide-induced tolerance in allogeneic transplantation: from basic studies to clinical application. Front Immunol. 10:3138.
   PubMed Web of Science ®Google Scholar
• Kim DH, Lerner A. 1998. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood. 92(7):2484–2494.
   PubMed Web of Science ®Google Scholar
• Kwon CH, Maddison K, LoCastro L, Borch RF. 1987. Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin. Cancer Res. 47(6):1505–1508.
   PubMed Web of Science ®Google Scholar
• Liang L, Beshay E, Prud'homme GJ. 1998. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. Diabetes. 47(4):570–575.
   PubMed Web of Science ®Google Scholar
• Lutsiak MEC, Semnani RT, De Pascalis R, Kashmiri SVS, Schlom J, Sabzevari H. 2005. Inhibition of CD4 + 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 105(7):2862–2868.
   PubMed Web of Science ®Google Scholar
• Madelian V, Vigne EL. 1996. Rapid regulation of a cyclic AMP-specific phosphodiesterase (PDE IV) by forskolin and isoproterenol in LRM55 astroglial cells. Biochem Pharmacol. 51(12):1739–1747.
   PubMed Web of Science ®Google Scholar
• Mazur DJ, Perrino FW. 1999. Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3'->5' exonucleases. J Biol Chem. 274(28):19655–19660.
   PubMed Web of Science ®Google Scholar
• McDiarmid MA, Iype PT, Kolodner K, Jacobson-Kram D, Strickland PT. 1991. Evidence for acrolein-modified DNA in peripheral blood leukocytes of cancer patients treated with cyclophosphamide. Mutat Res Mol Mech Mutagen. 248(1):93–99.
   PubMed Web of Science ®Google Scholar
• McGown AT, Fox BW. 1986. A proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in a Yoshida cell line in vitro. Cancer Chemother Pharmacol. 17(3):223–226.
   PubMed Web of Science ®Google Scholar
• Omori K, Kotera J. 2007. Overview of PDEs and their regulation. Circ Res. 100(3):309–327.
   PubMed Web of Science ®Google Scholar
• Reha-Krantz LJ, Nonay RL. 1993. Genetic and biochemical studies of bacteriophage T4 DNA polymerase 3’–>5’-exonuclease activity. J Biol Chem. 268(36):27100–27108.
   PubMed Web of Science ®Google Scholar
• Sakura M, Masuda H, Matsuoka Y, Yokoyama M, Kawakami S, Kihara K. 2009. Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats. BJU Int. 103(2):264–269.
   PubMed Web of Science ®Google Scholar
• Struck RF, Kirk MC, Witt MH, Laster WR. 1975. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Biomed Mass Spectrom. 2(1):46–52.
   PubMedGoogle Scholar
• Szczypka M. 2020. Role of phosphodiesterase 7 (PDE7) in T cell activity. Effects of selective PDE7 inhibitors and dual PDE4/7 inhibitors on T cell functions. Int J Mol Sci. 21(17):6118.
   PubMed Web of Science ®Google Scholar
• Tang M, Wang H, Hu Y, Chen W-S, Akao M, Feng Z, Hu W. 2011. Acrolein induced DNA damage, mutagenicity and effect on DNA repair. Mol Nutr Food Res. 55(9):1291–1300.
   PubMed Web of Science ®Google Scholar
• Tisdale MJ. 1977. Interaction of cyclophosphamide and its metabolites with adenosine 3',5'-monophosphate binding proteins. Biochem Pharmacol. 26(16):1469–1474.
   PubMed Web of Science ®Google Scholar
• Traverso I, Fenoglio D, Negrini S, Parodi A, Battaglia F, Kalli F, Conteduca G, Tardito S, Traverso P, Indiveri F, et al. 2012. Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells. Hum Immunol. 73(3):207–213.
   PubMed Web of Science ®Google Scholar
• Tsai-Turton M, Luong BT, Tan Y, Luderer U. 2007. Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. Toxicol Sci. 98(1):216–230.
   PubMed Web of Science ®Google Scholar
• Uzair B, Khan BA, Sharif N, Shabbir F, Menaa F. 2018. Phosphodiesterases (PDEs) from snake venoms: therapeutic applications. Protein Pept Lett. 25(7):612–618.
   PubMed Web of Science ®Google Scholar
• van Kan M, Burns KE, Browett P, Helsby NA. 2019. A higher throughput assay for quantification of melphalan-induced DNA damage in peripheral blood mononuclear cells. Sci Rep. 9(1):18912–18918.
   PubMed Web of Science ®Google Scholar
• Vigone G, Shuhaibar LC, Egbert JR, Uliasz TF, Movsesian MA, Jaffe LA. 2018. Multiple cAMP phosphodiesterases act together to prevent premature oocyte meiosis and ovulation. Endocrinology. 159(5):2142–2152.
   PubMed Web of Science ®Google Scholar
• Voelcker G. 2017. Enzyme catalyzed decomposition of 4-hydroxycyclophosphamide. Open Conf Proc J. 8(1):44–51.
   Google Scholar
• Voelcker G, Bielicki L, Hohorst HJ. 1981. Evidence for enzymatic toxification of activated cyclophosphamide (4-hydroxycyclophosphamide). J Cancer Res Clin Oncol. 99(3):A58–A59.
   Web of Science ®Google Scholar
• Wang P, Wu P, Ohleth KM, Egan RW, Billah MM. 1999. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol. 56(1):170–174.
   PubMed Web of Science ®Google Scholar
• Wei D, Fabris D, Fenselau C. 1999. Covalent sequestration of phosphoramide mustard by metallothionein—an in vitro study. Drug Metab Dispos. 27(7):786–791.
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Parton S, Schafer P. 2012. Phosphodiesterase 4 expression in rheumatoid arthritis synovium and anti-inflammatory effects of apremilast on synovial fibroblasts. ACR Meet Abstr. 2012:A51.
   Google Scholar
• Yigitaslan S, Ozatik O, Ozatik FY, Erol K, Sirmagul B, Baseskioglu AB. 2014. Effects of tadalafil on hemorrhagic cystitis and testicular dysfunction induced by cyclophosphamide in rats. Urol Int. 93(1):55–62.
   PubMed Web of Science ®Google Scholar
• Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B. 2010. Selective depletion of CD4 + CD25 + Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res. 70(12):4850–4858.
   PubMed Web of Science ®Google Scholar
• Zon G, Ludeman SM, Brandt JA, Boyd VL, Ozkan G, Egan W, Shao KL. 1984. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and the concomitant partitioning of aldophosphamide between irreversible fragmentation and reversible conjugation pathways. J Med Chem. 27(4):466–485.
   PubMed Web of Science ®Google Scholar